Streetbeat News

Analyst Ratings

UPWK

Upwork, Inc. (NASDAQ:UPWK) reported strong Q4 results, surpassing analyst estimates for earnings and sales. The company's earnings were 20 cents per share against an expected 17 cents, with sales at $183.9 million versus the anticipated $178.16 million. Upwork's optimistic outlook for Q1 and full-year 2024, including higher earnings and revenue forecasts, was also highlighted. Despite this, UPWK shares fell 7.2% following the announcement. Analysts from Needham and RBC Capital raised their price targets for Upwork, reflecting confidence in its growth trajectory.

Portfolio Pulse from Avi Kapoor

February 15, 2024 | 6:20 pm

WST

West Pharmaceutical Services Inc. (WST) reported a Q4 2023 adjusted EPS of $1.83, surpassing estimates but with sales slightly missing expectations. The company provided a cautious 2024 outlook, forecasting lower sales and EPS than consensus estimates, attributing this to moderated organic sales growth and inventory management challenges. Despite this, analysts at William Blair maintain an Outperform rating, emphasizing the need for West to clarify its position on destocking to reassure investors.

Portfolio Pulse from Vandana Singh

February 15, 2024 | 6:17 pm

UPXI

Alliance Global Partners analyst Aaron Grey downgraded Upexi (NASDAQ:UPXI) from Buy to Neutral and reduced the price target from $3 to $1.25.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 6:10 pm

FSLY

Craig-Hallum analyst Jeff Van Rhee downgrades Fastly (NYSE:FSLY) from Buy to Hold and sets a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 6:07 pm

ENTG

Craig-Hallum analyst Christian Schwab upgrades Entegris (NASDAQ:ENTG) from Hold to Buy and sets a price target of $150.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 6:02 pm

GM

In the last three months, 13 analysts have published diverse ratings on General Motors (NYSE:GM), with a mix of bullish to bearish sentiments. The average 12-month price target for GM has been raised to $49.87, up from $48.55. Analysts from firms like Tigress Financial, Wedbush, and Goldman Sachs have adjusted their ratings and price targets, reflecting a nuanced view of GM's market position and financial health. Despite facing challenges like a slight revenue decline and high debt levels, GM's strong net margin, ROE, and ROA indicate solid profitability and financial performance.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 6:01 pm

LAD

Four financial analysts have recently shared mixed evaluations of Lithia Motors (NYSE:LAD), with ratings ranging from 'Somewhat Bullish' to 'Indifferent'. Over the last three months, there has been a shift towards a more cautious stance, with the latest ratings being 'Indifferent'. Analysts have adjusted their 12-month price targets for LAD, now averaging $356.0, marking a 19.06% increase from the previous target of $299.00. Lithia Motors has shown strong financial performance, with significant revenue growth, high net margin, and impressive ROE and ROA, outperforming industry averages. The company's debt-to-equity ratio is below the industry average, indicating a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 6:01 pm

AMGN

Financial giants have shown a bearish stance on Amgen (NASDAQ:AMGN) through options trading, with 83% of trades being bearish. The trading activity focuses on a price range between $125.0 and $292.5. Amgen, a leader in biotechnology-based human therapeutics, has seen its stock price slightly decrease by -0.68%, currently at $288.1. Analysts have mixed ratings on AMGN, with target prices ranging from $278 to $350. The next earnings report is expected in 70 days.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 6:00 pm

HCSG

Healthcare Services Group (NASDAQ:HCSG) has received mixed reviews from 5 financial analysts over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target for HCSG has been raised to $13.6, indicating a 16.54% increase from the previous target of $11.67. Analysts from firms including UBS, RBC Capital, Baird, and Benchmark have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Despite facing challenges in revenue growth and asset utilization, HCSG maintains a strong net margin and ROE, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 6:00 pm

HOOD

Recent options trading trends for Robinhood Markets (NASDAQ:HOOD) show a bearish sentiment among whales, with 58% of trades being bearish and 41% bullish. Significant trading activity has targeted a price range of $10.0 to $25.0. The stock is currently trading at $13.4, with a volume of 13,899,768 and may be overbought according to RSI readings. Analysts have issued varied ratings, with a consensus target price of $15.1, ranging from $25 to $11.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 6:00 pm